{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:55:35Z","timestamp":1762012535477,"version":"build-2065373602"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00508-019-1493-6","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T08:03:57Z","timestamp":1555056237000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostik und Therapie des Typ\u00a01 Diabetes mellitus (Update\u00a02019)","Diagnosis and insulin therapy of type\u00a01 diabetes mellitus (Update\u00a02019)"],"prefix":"10.1007","volume":"131","author":[{"given":"Monika","family":"Lechleitner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Hoppichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimund","family":"Weitgasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Winhofer-St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kautzky-Willer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guntram","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Prager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Wascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"key":"1493_CR1","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"ADA","year":"2018","unstructured":"ADA. Classification and diagnosis of diabetes. Standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41:S13\u2013S26.","journal-title":"Diabetes Care"},{"key":"1493_CR2","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2337\/dc14-1140","volume":"37","author":"JL Chiang","year":"2014","unstructured":"Chiang JL, Kirkman MS, Laffel LMB, Peters AL, Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a\u00a0position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034\u201354.","journal-title":"Diabetes Care"},{"key":"1493_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrendo.2017.99","volume":"13","author":"R Buzzetti","year":"2017","unstructured":"Buzzetti R, Zampetti S, Maddaloni E. Adults-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13:674\u201386.","journal-title":"Nat Rev Endocrinol"},{"key":"1493_CR4","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","volume":"391","author":"LA DiMeglio","year":"2018","unstructured":"DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391:2449\u201362.","journal-title":"Lancet"},{"key":"1493_CR5","first-page":"e938","volume":"133","author":"D Dabelea","year":"2014","unstructured":"SEARCH for Diabetes in Youth Study Group, Dabelea D, Rewers A, Stafford JM, et\u00a0al. Trends in the prevalence of ketoacidosis in diabetes diagnosis: the SEARCH for Diabetes in the Youth Study. Pediatr Electron Pages. 2014;133:e938\u201345.","journal-title":"Pediatr Electron Pages"},{"key":"1493_CR6","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"Ziegler AG, Rewers M, Simell O, et\u00a0al. Seroconversion to multiple islet autoantibodies and its progression to diabetes. JAMA. 2013;309:2473\u20134.","journal-title":"JAMA"},{"key":"1493_CR7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/S0140-6736(10)60550-8","volume":"375","author":"CN Mbanya","year":"2010","unstructured":"Mbanya CN, Motala AA, Sobngwi W, Assah FK, Enaru ST. Diabetes in sub-Saharan Africa. Lancet. 2010;375:2254\u201366.","journal-title":"Lancet"},{"key":"1493_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/dme.12700","volume":"32","author":"E Laugensen","year":"2015","unstructured":"Laugensen E, Ostergaard JA, Leslie RD, Danish Diabetes Academy Workshop and Workshop Speakers. Latent autoimmune diabetes of the adults: current knowledge and uncertainity. Diabetes Med. 2015;32:843\u201353.","journal-title":"Diabetes Med"},{"key":"1493_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrendo.2017.99","volume":"13","author":"R Buzzetti","year":"2017","unstructured":"Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13:674\u201386.","journal-title":"Nat Rev Endocrinol"},{"key":"1493_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1210\/jc.2017-01706","volume":"103","author":"OP Zaharia","year":"2018","unstructured":"Zaharia OP, Bobrov P, STrassburger K, Bodis K, Karusheva Y, Scholz M, Markgraf DF, Burkart V, Schloot NC, M\u00fcssig K, Szendroedi J, Roden M, GDS Group. Metabolic characteristics of recently diagnosed adult-onset autoimmune diabetes mellitus. J\u00a0Clin Endocrinol Metab. 2018;103:429\u201337.","journal-title":"J Clin Endocrinol Metab"},{"key":"1493_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/db07-0299","volume":"57","author":"C Cervin","year":"2008","unstructured":"Cervin C, Lyssenko V, Bakhtadze E, et\u00a0al. Genetic similarities between latent autoimmune diabetes in adults, type 1, and type 2 diabetes. Diabetes. 2008;57:1433\u20137.","journal-title":"Diabetes"},{"key":"1493_CR12","first-page":"46","volume-title":"Insulin therapy in type 1 diabetes","author":"A Cheng","year":"2008","unstructured":"Cheng A, Hanna A, Kader T, Richardson S. Insulin therapy in type 1 diabetes. 2008. S.\u00a046\u201352. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee."},{"key":"1493_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrendo.2017.39","volume":"13","author":"C Mathieu","year":"2017","unstructured":"Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol. 2017;13:385\u201399.","journal-title":"Nat Rev Endocrinol"},{"key":"1493_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2213-8587(14)70073-7","volume":"2","author":"U Pedersen-Bjergaard","year":"2014","unstructured":"Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, Norgaard K, Perrild H, Christiansen JS, Jensen T, Hougaard P, Parvin HH, Thorsteinsson B, Tarnow L. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a\u00a0prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014;2:553\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1493_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.diabet.2016.03.001","volume":"42","author":"RM Agesen","year":"2016","unstructured":"Agesen RM, Kristensen PL, Beck-Nielsen H, Norgaard K, Perrild H, Christiansen JS, Jensen T, Hougaard P, Parving HH, Thorsteinsson B, Tranow L, Pedersen-Biergaard U. Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: the HypoAna trial. Diabetes Metab. 2016;42:249\u201355.","journal-title":"Diabetes Metab"},{"key":"1493_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dme.13317","volume":"34","author":"PL Kristensen","year":"2017","unstructured":"Kristensen PL, Tarnow L, Bay C, Norgaard K, Jensen T, Parving HH, Perrild H, Beck-Nielsen H, Christiansen JS, Thorsteinsson B, Pedersen-Bjegaard U. Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia-prone people with type 1 diabetes. Diabet Med. 2017;34:625\u201331.","journal-title":"Diabet Med"},{"key":"1493_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012161","author":"B Fullerton","year":"2016","unstructured":"Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, Plank J, Pieber TR, Gerlach FM. Short-acting insulin analogies versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016; https:\/\/doi.org\/10.1002\/14651858.CD012161 .","journal-title":"Cochrane Database Syst Rev"},{"key":"1493_CR18","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1111\/dom.13270","volume":"20","author":"A Basu","year":"2018","unstructured":"Basu A, Pieber TR, Hansen AK, SAch-Friedl S, Erichsen L, Basu R, Haahr H. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. Diabetes Obes Metab. 2018;20:1615\u201322.","journal-title":"Diabetes Obes Metab"},{"key":"1493_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2337\/dc16-1771","volume":"40","author":"D Russel-Jones","year":"2017","unstructured":"Russel-Jones D, Bode BW, DeBlock C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Osterskov AB, Graungaard T, Bergenstal RM. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a\u00a026-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017;40:943\u201350.","journal-title":"Diabetes Care"},{"key":"1493_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2337\/dc16-1770","volume":"40","author":"K Bowering","year":"2017","unstructured":"Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster aspart versus insulin aspart as part of a\u00a0basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2trial. Diabetes Care. 2017;40:951\u20137.","journal-title":"Diabetes Care"},{"key":"1493_CR21","first-page":"213","volume":"2","author":"K Poon","year":"2010","unstructured":"Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogues. Drug Healthc Patient Saf. 2010;2:213\u201323.","journal-title":"Drug. Healthc. Patient Saf."},{"key":"1493_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","volume":"81","author":"M Monami","year":"2008","unstructured":"Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH insulin in type 2 diabetes: a\u00a0meta-analysis. Diabetes Res Clin Pract. 2008;81:184\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"1493_CR23","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2337\/diacare.26.3.590","volume":"26","author":"P Vague","year":"2003","unstructured":"Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a\u00a0basal-bolus regimen with premeal aspart. Diabetes Care. 2003;26:590\u20136.","journal-title":"Diabetes Care"},{"key":"1493_CR24","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.clinthera.2017.01.007","volume":"39","author":"VC Woo","year":"2017","unstructured":"Woo VC. A review of the clinical efficacy and safety of insulin degludec and glargine 300\u202fU\/mL in the treatment of diabetes mellitus. Clin Ther. 2017;39:S12\u2013S33.","journal-title":"Clin Ther"},{"key":"1493_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40265-016-0541-z","volume":"76","author":"HA Blair","year":"2016","unstructured":"Blair HA, Keating GM. Insulin Glargine 300\u202fU\/mL: a\u00a0review in diabetes mellitus. Drugs. 2016;76:363\u201374.","journal-title":"Drugs"},{"key":"1493_CR26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.2165\/11642240-000000000-00000","volume":"72","author":"JD Robinson","year":"2012","unstructured":"Robinson JD, Neumiller JJ, Campbell RK. Can a\u00a0new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin deglutec? Drugs. 2012;72:2319\u201325.","journal-title":"Drugs"},{"key":"1493_CR27","first-page":"389","volume":"12","author":"EM Lamos","year":"2016","unstructured":"Lamos EM, Younk LM, Davis STN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389\u2013400.","journal-title":"Ther Clin Risk Manag"},{"key":"1493_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2337\/dc16-0684","volume":"40","author":"RM Bergenstal","year":"2017","unstructured":"Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, et\u00a0al. Comparison of insulin glargine 300 units\/mL and 100 units\/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care. 2017;40:554\u201360.","journal-title":"Diabetes Care"},{"key":"1493_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.diabres.2017.06.003","volume":"133","author":"M Rodacki","year":"2017","unstructured":"Rodacki M, Carvalho RM, Zajdenverg L. The potential effect of ultra-long insulin degludec on glycaemic variability. Diabetes Res Clin Pract. 2017;133:92\u2013103.","journal-title":"Diabetes Res Clin Pract"},{"key":"1493_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00125-017-4312-5","volume":"60","author":"A But","year":"2017","unstructured":"But A, De Bruin ML, Bazelier MT, et al. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia. 2017;60:1691\u2013703.","journal-title":"Diabetologia"},{"key":"1493_CR31","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00125-009-1568-4","volume":"52","author":"A Degaard","year":"2009","unstructured":"Degaard A, Lynggaard H, Rastam A, et al. No evidence of inscreased risk of malignancies in patients with diabetes treated with insulin detemir: a\u00a0meta-analysis. Diabetologia. 2009;52:2507\u201312.","journal-title":"Diabetologia"},{"key":"1493_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N\u00a0Engl J Med. 1993;329:977\u201388.","journal-title":"N Engl J Med"},{"key":"1493_CR33","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Study Research Group, Nathan DM, Cleary PA, Backlung JYC, et\u00a0al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N\u00a0Engl J Med. 2005;353:2643\u201353.","journal-title":"N Engl J Med"},{"key":"1493_CR34","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/dc15-2399","volume":"39","author":"Diabetes Control and Complications trial (DCCT)","year":"2016","unstructured":"Diabetes Control and Complications trial (DCCT), Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT\/EDIC versus the general populations. Diabetes Care. 2016;39:1378\u201383.","journal-title":"Diabetes Care"},{"key":"1493_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/BF01788901","volume":"30","author":"YT Kryszynska","year":"1987","unstructured":"Kryszynska YT, Home PD, Hanning I, Alberti KGMM. Basal and 24-h C\u2011peptide and insulin secretion rate in nomal man. Diabetologia. 1987;30:16\u201321.","journal-title":"Diabetologia"},{"key":"1493_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2337\/dc11-1739","volume":"35","author":"G Gruden","year":"2012","unstructured":"Gruden G, Giunti S, Baritta F, et\u00a0al. QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study. Diabetes Care. 2012;35:125\u20137.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"1493_CR37","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.2337\/dc11-s213","volume":"34","author":"P Pozzili","year":"2011","unstructured":"Pozzili P, Guglielmi C, Caprio S, Buzzetti R. Obesity, autoimmunity, and double diabetes in youth. Diabetes Care. 2011;34(Suppl 2):S166\u2013S70.","journal-title":"Diabetes Care"},{"key":"1493_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.diabres.2016.06.003","volume":"119","author":"SR Merger","year":"2016","unstructured":"Merger SR, Kerner W, Stadler M, Zeyfang A, Jehle P, M\u00fcller-Korbsch M, Holl RW, DPD Initiative, German Competence Network Diabetes mellitus. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016;119:48\u201356.","journal-title":"Diabetes Res Clin Pract"},{"key":"1493_CR39","doi-asserted-by":"publisher","first-page":"e0137525","DOI":"10.1371\/journal.pone.0137525","volume":"10","author":"BU Nwosi","year":"2015","unstructured":"Nwosi BU, Maranda L, Cullen K, Greenman L, Flechman L, McShea N, Barton BA, Lee MM. A randomized double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight\/obese youth with type 1 diabetes. PLoS One. 2015;10:e137525.","journal-title":"PLoS One"},{"key":"1493_CR40","first-page":"376","volume":"67","author":"A Driessche Van den","year":"2009","unstructured":"Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a\u00a0clinical review. Neth J Med. 2009;67:376\u201387.","journal-title":"Neth J Med"},{"key":"1493_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00108-012-3174-7","volume":"54","author":"I Heukamp","year":"2013","unstructured":"Heukamp I, Then C, Lechner A, Seissler J. Update Typ-1-Diabetes. Internist. 2013;54:201\u201316.","journal-title":"Internist"},{"key":"1493_CR42","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1515\/9783110228656.177","volume-title":"Autoimmune diagnostics","author":"M Schott","year":"2012","unstructured":"Schott M, Seissler J. Autoimmune polyendocrine syndromes. In: Renz H, Hrsg. Autoimmune diagnostics. Berlin: De Gruyter; 2012. S. S177\u2013S89."},{"key":"1493_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/dme.12318","volume":"31","author":"CB Shun","year":"2014","unstructured":"Shun CB, Donaghue KC, Phelan H, Twigg SM, Craig ME. Thyroid autoimmunity in type 1 diabetes: systematic review and meta-analysis. Diabet Med. 2014;31:126\u201335.","journal-title":"Diabet Med"},{"key":"1493_CR44","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1056\/NEJMra030158","volume":"350","author":"GS Eisenbarth","year":"2004","unstructured":"Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N\u00a0Engl J Med. 2004;350:2068\u201379.","journal-title":"N Engl J Med"},{"key":"1493_CR45","doi-asserted-by":"publisher","first-page":"850","DOI":"10.2337\/diacare.28.4.850","volume":"28","author":"JM Barker","year":"2005","unstructured":"Barker JM, Yu L, et al. Autoantibody \u201csubspecificity\u201d in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 2005;28:850\u20135.","journal-title":"Diabetes Care"},{"key":"1493_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ng0994-83","volume":"8","author":"J Aaltonen","year":"1994","unstructured":"Aaltonen J, Bjorses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nat Genet. 1994;8:83\u20137.","journal-title":"Nat Genet"},{"key":"1493_CR47","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/dc10-1756","volume":"34","author":"TM Triolo","year":"2011","unstructured":"Triolo TM, Armstrong TK, McFann K, Yu L, Rewers MJ, Klingensmith GJ, Eisenbarth GS, Barker JM. Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care. 2011;34:1211\u20133.","journal-title":"Diabetes Care"},{"key":"1493_CR48","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2337\/diacare.26.4.1181","volume":"26","author":"GE Umipierrez","year":"2003","unstructured":"Umipierrez GE, Latif KA, Murphy MB, et\u00a0al. Thyroid dysfunction in patients with type 1 diabetes: a\u00a0longitudinal study. Diabetes Care. 2003;26:1181\u20135.","journal-title":"Diabetes Care"},{"key":"1493_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1399-5448.2007.00249.x","volume":"8","author":"O Kordonouri","year":"2007","unstructured":"Kordonouri O, Maguire AM, Knip M, Schober E, Lorini R, Holl RW, Donaghue KC, Other complications and associated conditions. ISPAD clinical practice consensus guidelines 2006\u20132007. Pediatr Diabetes. 2007;8:171\u20136.","journal-title":"Pediatr Diabetes"},{"key":"1493_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s001250051291","volume":"42","author":"V Lampasona","year":"1999","unstructured":"Lampasona V, Bonfanti R, Bazzigaluppi E, et\u00a0al. Antibodies to tissue transglutaminase C in type 1 diabetes. Diabetologia. 1999;42:1195\u20138.","journal-title":"Diabetologia"},{"key":"1493_CR51","first-page":"189","volume":"7","author":"S Hogg-Kollars","year":"2014","unstructured":"Hogg-Kollars S, Al Dulaimi D, Tait K, Rostami K. Type 1 diabetes mellitus and gluten induced disorders. Gastroenterol Hepatol Bed Bench. 2014;7:189\u201397.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"1493_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2337\/diacare.26.1.82","volume":"26","author":"C DeBlock","year":"2003","unstructured":"DeBlock C, de Leeuw I, Bogers J, et\u00a0al. Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. Diabetes Care. 2003;26:82\u20138.","journal-title":"Diabetes Care"},{"key":"1493_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1677\/joe.0.1170467","volume":"117","author":"C Betterle","year":"1988","unstructured":"Betterle C, Scalici C, Presotto F, et\u00a0al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J\u00a0Endocrinol. 1988;117:467\u201375.","journal-title":"J Endocrinol"},{"key":"1493_CR54","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1365-2133.2008.08881.x","volume":"159","author":"DJ Gawkrodger","year":"2008","unstructured":"Gawkrodger DJ, Ormerod AD, Shaw L, et\u00a0al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051\u201376.","journal-title":"Br J Dermatol"},{"key":"1493_CR55","first-page":"242","volume":"21","author":"E Valletta","year":"2011","unstructured":"Valletta E, Fornaro M, Pecori S, Zanoni G. Selective immunoglobulin A deficiency and celiac disease: let\u2019s give serology a\u00a0chance. J\u00a0Investig Allergol Clin Immunol. 2011;21:242\u20134.","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"1493_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00005176-200004000-00008","volume":"30","author":"E Schober","year":"2000","unstructured":"Schober E, Bittmann B, Granditsch G, Huber VVD, H\u00fcppe A, J\u00e4ger A, Oberhuber G, Rami B, Reichel G. Screening by enti-endomysium antibody for celiac disease in diabetic children and adolescents in Austria. J Pediatr Gastroenterol Nutr. 2000;30:391\u20136.","journal-title":"J. Pediatr. Gastroenterol. Nutr."}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1493-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-019-1493-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1493-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T20:49:48Z","timestamp":1663274988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-019-1493-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":56,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s00508-019-1493-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"12 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Lechleitner hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards erhalten: Boehringer Ingelheim, Novo Nordisk, Sanofi. S.\u00a0Kaser hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis, Servier, Takeda. F.\u00a0Hoppichler hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Janssen, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, Servier, Takeda. M.\u00a0Roden hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Genentech, Merck, Novartis, Novo Nordisk, Nutricia\/Danone, Poxel, sanofi-aventis. R.\u00a0Weitgasser hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, Allergan, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, MSD, Novo Nordisk, Roche, Sanofi, Servier, Takeda. B.\u00a0Ludvik hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott Austria, Aengus, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Medtronic, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis, Servier, Takeda. P.\u00a0Fasching hat Vortragshonorare und Honorare f\u00fcr Beratungst\u00e4tigkeit von folgenden Firmen erhalten: AstraZeneca, Boehringer Ingelheim, MSD, Novartis, Takeda, Servier, Eli Lilly, Novo Nordisk, Sanofi. Y.\u00a0Winhofer-St\u00f6ckl hat von folgenden Firmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und Beratung erhalten: Amgen, AstraZeneca, Eli Lilly, Novartis, Sanofi. A.\u00a0Kautzky-Willer hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis, Servier, Takeda. G.\u00a0Schernthaner hat Lectures gehalten f\u00fcr: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Mundipharma, Novo Nordisk, Servier, Takeda. R.\u00a0Prager hat in den letzten 36\u00a0Monaten von folgenden Firmen Honorare\/Forschungsgelder erhalten: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Medtronic, Merck-Sharp & Dohme, Novartis, Novo Nordisk, sanofi-aventis, Takeda. T.C.\u00a0Wascher hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, Amgen, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mylan, Novo Nordisk, sanofi aventis, Takeda. M.\u00a0Clodi hat Vortragshonorare und Honorare f\u00fcr Beratungst\u00e4tigkeit von folgenden Firmen erhalten: Eli Lilly, AstraZeneca, Boehringer Ingelheim, Amgen, Sanofi, Novo Nordisk, Servier.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}